TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.…
TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences (NASDAQ: HURA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 22 employees.
The shares were at 1.250 USD on 20 November 2026, down 50.4% over 52 weeks. Its 52-week range is 0.4100 USD to 3.430 USD: the price is 63.6% below the high and 204.9% above the low.
Its market capitalisation is 82.20M USD.
TuHURA Biosciences reports return on equity of -143.6% and an operating margin of 0.0%.
Its debt exceeds its cash by 8.00M USD, a debt-to-equity ratio of 0.03. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 30 March 2027.